Feasibility and efficacy of delayed pharmacoinvasive therapy for ST-elevation myocardial infarction

doi:10.4330/wjc.v15.i1.23

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 15, Issue 1

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (4399)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-1) series, Tables (1-4) series.

Item

Count

PDF

218

WORD

HTML

1777

Figures (1-1)

327

Tables (1-4)

311

Sum=2678

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

182

Download

680

Sum=862

Publishing Process of This Article

Item

Count

Browse

236

Download

623

Sum=859

Jan 26, 2023 (publication date) through Feb 21, 2025

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Cardiology

ISSN

1949-8462

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Prospective Study

World J Cardiol. Jan 26, 2023; 15(1): 23-32
Published online Jan 26, 2023. doi: 10.4330/wjc.v15.i1.23

Table 4 Univariate analysis for prediction of primary endpoints as a measure of outcome

Variable	Events (16/183)	Routine (3-24 h)	Events (21/154)	Delayed (> 24 h)
Variable	Events (16/183)	OR (95%CI)	Events (21/154)	OR (95%CI)
Age (> 65 yr)	1/16	0.68 (0.08-5.48)	3/18	1.31 (0.34-4.98)
Age (55-65 yr)	9/81	1.70 (0.62-4.77)	8/47	1.48 (0.57-3.86)
Age (45-55 yr)	1/41	0.21 (0.03-1.65)	5/56	0.50 (0.17-1.46)
Age (35-45 yr)	4/38	1.30 (0.40-4.30)	4/26	1.19 (0.36-3.87)
Age (< 35 yr)	1/7	1.79 (0.20-15.86)	1/7	1.06 (0.12-9.26)
Male	15/160	2.28 (0.29-18.10)	17/138	0.42 (0.12-1.46)
KILLIP Class-1	13/165	0.43 (0.11-1.67)	17/132	0.67 (0.20-2.20)
KILLIP Class-2	3/11	4.59 (1.08-19.40)	1/9	0.78 (0.09-6.59)
AWMI	9/99	1.10 (0.39-3.09)	10/88	0.64(0.25-1.61)
Type 2 DM	3/37	0.9 (0.24-3.35)	2/34	0.33(0.07-1.50)
Smoking	10/100	1.43 (0.50-4.10)	14/86	1.69 (0.64-4.47)
HTN	4/49	0.90 (0.28-2.95)	4/43	0.57 (0.18-1.79)
LVEF (35-45)	3/70	0.34 (0.09-1.25)	7/73	0.51 (0.19-1.34)
LVEF (> 45)	12/112	2.01 (0.62-6.50)	14/78	2.16 (0.82-5.68)
MVD	7/78	1.05 (0.37-2.96)	11/65	1.61 (0.64-4.05)
SVD	9/98	1.13 (0.40-3.17)	10/87	0.66 (0.26-1.66)
CrCl (30-60)	1/29	0.33 (0.04-2.61)	5/30	1.35 (0.45-4.03)
CrCl (60-90)	11/113	1.40 (0.47-4.22)	11/78	1.08 (0.43-2.72)
CrCl (> 90)	4/40	1.21 (0.37-3.99)	5/42	0.81 (0.28-2.37)

AWMI: Anterior wall ST-elevation myocardial infarction; DM: Diabetes mellitus; HTN: Hypertension; LVEF: Left ventricular ejection fraction; MVD: Multi-vessel disease; SVD: Single vessel disease; CrCL: Creatinine clearance.

Citation: Sethi R, Mohan L, Vishwakarma P, Singh A, Sharma S, Bhandari M, Shukla A, Sharma A, Chaudhary G, Pradhan A, Chandra S, Narain VS, Dwivedi SK. Feasibility and efficacy of delayed pharmacoinvasive therapy for ST-elevation myocardial infarction. World J Cardiol 2023; 15(1): 23-32
URL: https://www.wjgnet.com/1949-8462/full/v15/i1/23.htm
DOI: https://dx.doi.org/10.4330/wjc.v15.i1.23